Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
92
resultados
Última actualización
28/08/2026 [07:42:00]
Resultados 75 a 92 de 92
Resumen de: CN121987795A
The invention discloses an application of an IP6K1 gene, an IP6K1 protein and a PAS-A protein fragment in screening and preparing a medicine for preventing and/or treating myocardial infarction diseases or a medicine for improving myocardial cell injury caused by hypoxia. Through research, it is found for the first time that IP6K1 protein is directly combined with a PAS-A substructure domain of HIF-1alpha, and then degradation of the HIF-1alpha, formation of HIF-1alpha/ARNT dimer and combination of the HIF-1alpha and p53 are affected, so that repair of myocardial cell damage caused by hypoxia by the HIF-1alpha is limited, and cell death is aggravated; therefore, the influence caused by myocardial infarction is aggravated. When the IP6K1 gene is knocked out, or the expression of the IP6K1 gene is inhibited, or the IP6K1 protein is degraded, or the expression of a subdomain PAS-A protein fragment of the HIF-1alpha is increased, the combination of the IP6K1 protein and the HIF-1alpha can be eliminated, so that the positive effect of the HIF-1alpha is improved, the repair of myocardial cell injury is improved, the cell survival is promoted, and the adverse influence caused by myocardial infarction is reduced.
Resumen de: CN121992094A
The invention relates to a molecular marker for diagnosis, prognosis evaluation and treatment of cardiac fibrosis, and belongs to the technical field of biological medicines. The invention provides a molecular marker capable of diagnosing cardiac fibrosis, evaluating the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular diseases accompanied with cardiac fibrosis or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises a hepatocyte growth factor. Research finds that the HGF is remarkably increased in plasma of a patient with cardiac fibrosis, and the plasma HGF level of a patient with aortic valve stenosis is also remarkably increased before an operation, so that the HGF can be used for diagnosing cardiac fibrosis and evaluating the severity of cardiac fibrosis. Researches find that timely transient increase of the HGF in plasma of a patient with acute myocardial infarction is significantly related to good prognosis, and continuous low-level increase, continuous high-level increase, recurrence and delayed increase of the HGF are significantly related to poor prognosis, so that the HGF can be used for evaluating prognosis of acute myocardial infarction.
Resumen de: US20260128175A1
The present disclosure provides systems and methods for machine learning classification and assessment of disease based on gene expression data. In an aspect, a method for determining a disease state of a subject may comprise: (a) assaying a biological sample obtained or derived from the subject to produce a data set comprising gene expression measurements of the biological sample at each of a plurality of disease-associated genomic loci; (b) computer processing the data set to determine the disease state of the subject; and (c) electronically outputting a report indicative of the disease state of the subject. In some embodiments, the plurality of disease-associated genomic loci comprises single nucleotide polymorphisms (SNPs). In some embodiments, the disease comprises a lupus condition. In some embodiments, the disease comprises cardiovascular disease (CVD).
Resumen de: CN121971589A
The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.
Resumen de: CN121978331A
The invention belongs to the technical field of ischemic stroke treatment, and discloses application of ULK1 possibly serving as a target spot for treating ischemic stroke. According to the invention, a photothrombotic stroke model is established, a ULK1 inhibitor SBI-0206965 (SBI), LYN1604 hydrochloride (LYN) and a ULK1 agonist are administered, and the ULK1 agonist is used for regulating the activity of ULK1 in vivo. Examples assess the outcome of sensory motor deficits, neuronal apoptosis, and microglia/macrophage activated neurological function. Immunofluorescence detection results show that ULK1 is mainly located in microglial cells in a post-ischemic infarction area of China. Upregulated ULK1 is treated by LYN, so that the infarct volume is remarkably reduced, the motor function is improved, and the increase of inflammatory microglial cells is promoted. In conclusion, the ULK1 promotes the repair of neurons and promotes the formation of 13 paths of anti-inflammatory microglial cell paths after ischemic injury.
Resumen de: CN121978344A
The invention relates to application of a myocardial injury marker RSPO1 in preparation of a product for identifying cardiovascular diseases. The invention evaluates the expression profiles of all LGR4 ligands under cardiovascular diseases at present, provides the application of RSPO1 as a potential drug target, and further provides the application of the myocardial injury marker RSPO1 in preparation of products for identifying cardiovascular diseases based on the application. The invention also provides application of the reagent for detecting the RSPO1 protein level in preparation of products for diagnosing cardiovascular diseases. According to the invention, the problem of insufficient adaptability and specificity of the existing marker is solved, RSPO1 is developed into a diagnostic marker, a DY4645-05 ELISA kit is adopted for detection and adaptation of multiple samples such as serum, multiple cardiovascular diseases can be diagnosed, cross-species application is realized, a basic research and clinical diagnosis detection system is unified, and powerful support is provided for diagnosis and treatment of cardiovascular diseases.
Resumen de: CN121975930A
The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.
Resumen de: CN121975934A
The invention provides application of a reagent for detecting SNP sites in preparation of a product for detecting immunological rejection of organ transplantation patients. According to the present invention, the acute rejection reaction and the infection of the allogeneic organ transplantation patient can be simultaneously monitored, the genome concentration of the dd-cfDNA in the plasma can be quantified, the accurate detection of the dd-cfDNA of less than 0.5% can be achieved, the concentration calculation of the sample level can be performed on the dd-cfDNA, the sensitivity is high, and the stability is good. According to the system and the method, the physical condition of a patient subjected to allogeneic organ transplantation such as kidney transplantation, heart transplantation and lung transplantation after transplantation is regularly monitored, and a basis and a corresponding treatment scheme can be provided for dynamic monitoring and timely adjustment of the treatment scheme.
Resumen de: CN121975726A
The invention relates to a method for separating myocardial cell-derived small extracellular vesicles from in-vitro plasma in vitro and application of the myocardial cell-derived small extracellular vesicles. The method comprises the following steps: (1) providing a ligand capable of being specifically combined with a raney base receptor 2 protein RYR2; (2) separating total small cell extracellular vesicles from the in-vitro plasma sample; (3) co-incubating the ligand and total small extracellular vesicles, so that the ligand is specifically combined with the small extracellular vesicles which are derived from myocardial cells and express RYR2 on the surface, and a ligand-vesicle compound is formed; (4) combining the ligand-vesicle compound with a solid-phase carrier so as to separate the myocardial cell-derived extracellular vesicles of which the surfaces express RYR2 from the mixture; and (5) washing and/or eluting the ligand-vesicle compound combined on the solid-phase carrier to obtain enriched small extracellular vesicles derived from myocardial cells.
Resumen de: CN121975932A
The invention relates to a system and a method for ultrasensitive detection of microRNAs related to acute myocardial infarction. According to the method, the trans-cleavage activity of a designed circular RNA activator (CA-RNA) and Cas13a protein is utilized, Cas13a is activated through a target microRNA to cut a continuous uracil (U) structure in the CA-RNA, the circular conformation of the Cas13a is destroyed, a linear activator is released, and then multi-round cascade signal amplification is triggered. A centrifugal digital micro-fluidic chip is combined, a reaction system is divided into a large number of independent micro-chambers, positive micro-chambers are counted according to Poisson distribution, and accurate quantification of target microRNA is achieved. The system does not need reverse transcription and complex instruments, can complete detection within 15 minutes at 37 DEG C, has the detection limit reaching the almole level, has the advantages of simplicity and convenience in operation, high sensitivity, strong specificity, good universality and the like, and is suitable for early clinical diagnosis of acute myocardial infarction.
Resumen de: CN121975928A
The invention relates to a kit for screening dilated cardiomyopathy. The kit comprises a reagent for detecting one or more of genes of TP53, TNF, IL1beta, JUN, CD8A, TLR4, UBB, CTLA4, CXCL8 and NFKBIA. The kit provided by the invention is high in detection efficiency and low in detection cost, provides important reference basis for diagnosis and prognosis judgment of patients with dilated cardiomyopathy, and can remarkably improve the survival rate of the patients.
Resumen de: CN121971424A
The invention discloses a method for regulating and controlling pathological heart remodeling of an AAC model mouse by succinic acid, and belongs to the field of heart disease treatment. The method comprises the following steps: selecting 8-week-old male C57BL/6J mice, dividing the mice into a normal temperature group and a slight cold exposure group, and carrying out adaptive feeding; establishing a heart remodeling model through an AAC operation; performing 1.5% succinic acid aqueous solution and/or 1mg/mL broad-spectrum antibiotic intervention on the mouse for 4 weeks; the method comprises the following steps: collecting heart tissues, detecting heart remodeling related indexes through Masson staining, WGA staining, qPCR, Western blot and other methods, and evaluating an intervention effect. According to the invention, succinic acid is used for intervention in a slightly cold exposure environment, so that AAC model mouse pathological heart remodeling is effectively regulated and controlled, and a new method and thought are provided for research and treatment of heart remodeling diseases.
Resumen de: CN121975935A
The invention provides a primer composition for detecting hereditary thrombophilia related gene mutation and application of the primer composition, and relates to the technical field of gene detection. The primer composition comprises a PCR (Polymerase Chain Reaction) amplification primer and an extension primer, wherein the PCR amplification primer is used for carrying out specific amplification on 24 single nucleotide polymorphic sites of 22 genes, and the extension primer is used for carrying out single base extension on the 24 single nucleotide polymorphic sites. According to the primer composition, by selecting twenty-four specific loci of twenty-two genes covering key systems such as coagulation, anticoagulation and the like, a detection system which is adaptive to genetic characteristics of specific people and takes pathopoiesis and risk factors into account is constructed, so that the limitation of race heterogeneity of conventional indexes is effectively overcome; and major mutation and a multi-gene minor accumulation effect can be captured at the same time, so that individual genetic susceptibility is comprehensively analyzed, and a systematic and accurate basis is provided for accurate screening and diagnosis and treatment of hereditary thrombophilia.
Resumen de: CN121951024A
The invention provides a method for predicting myocarditis by using circular RNAcirc0071542 and ribosomal protein RPL13A. The method comprises the following steps: a) obtaining a biological sample of a subject; b) detecting the expression level of circACSL1 in the biological sample; c) comparing the expression level of the circACSL1 with a reference value from a healthy control; and d) when the expression level of the circACSL1 is higher than the reference value, judging that the subject has a myocarditis risk or is in a myocarditis state according to a difference value between the expression level of the circACSL1 and the reference value. The circACSL1 expression level is compared with the typical expression range of a dilated cardiomyopathy (DCM) subject to generate differential diagnosis data, and the expression difference of the marker between myocarditis and DCM can be utilized to effectively assist in clinically distinguishing the two diseases with different treatment strategies and prognosis but similar clinical manifestations.
Resumen de: CN121951022A
The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.
Resumen de: CN121951028A
The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting hypertrophic cardiomyopathy and a detection method and application thereof. The invention provides a marker for hypertrophic cardiomyopathy, the marker is CHAtRF, and the nucleotide sequence of the marker is as shown in SEQ ID NO: 1. The CHAtRF antisense nucleotide CHAtRF antiagomir can be used as an active ingredient in a product for treating hypertrophic cardiomyopathy. By using the CHAtRF antiagomir, the expression of CHAtRF in the heart can be inhibited, pathological myocardial hypertrophy can be remarkably inhibited, the fibrosis area can be reduced, and the effect of improving the heart function can be achieved, so that the purpose of preparing the medicine for preventing and/or treating hypertrophic cardiomyopathy by using the CHAtRF antiagomir as a novel gene therapy technology is achieved; and a new drug action target is provided for treatment of heart diseases related to hypertrophic cardiomyopathy.
Nº publicación: WO2026086863A1 30/04/2026
Solicitante:
THE CHINESE UNIV OF HONG KONG [CN]
BAKER HEART AND DIABETES INST [AU]
THE CHINESE UNIVERSITY OF HONG KONG
BAKER HEART AND DIABETES INSTITUTE
Resumen de: WO2026086863A1
Disclosed are a method for assessing genomic DNA methylation status in a subject, a method for assessing risk for coronary heart disease (CHD) and a kit for detecting CHD or assessing CHD risk in a subject diagnosed or known risk for type 2 diabetes.
BOPI
Sede Electrónica
